Christopher Haqq
Chief Tech/Sci/R&D Officer bei ELICIO THERAPEUTICS, INC.
Vermögen: - $ am 31.03.2024
Profil
Christopher M.
Haqq is currently the Chief Medical Officer & Executive Vice President at Elicio Therapeutics, Inc. (United States) and the Chief Medical Officer, EVP & Head-Research at Elicio Therapeutics, Inc. He previously held positions as an Independent Director at Consonance-HFW Acquisition Corp., Manager-Early Development Oncology Group at Amgen, Inc., Vice President-Clinical Research & Development at Cougar Biotechnology, Inc., Assistant Professor at The University of California, San Francisco, Vice President-Clinical Research & Development at Janssen Oncology, Inc., and Chief Scientific Officer, Executive VP-R&D at Atara Biotherapeutics, Inc. Dr. Haqq received his undergraduate degree from Stanford University and his doctorate from Harvard Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ELICIO THERAPEUTICS, INC
-.--% | 01.02.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Christopher Haqq
| Unternehmen | Position | Beginn |
|---|---|---|
| ELICIO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.10.2019 |
Elicio Therapeutics, Inc. (Old)
 Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01.10.2019 |
Ehemalige bekannte Positionen von Christopher Haqq
| Unternehmen | Position | Ende |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 25.10.2019 |
Janssen Oncology, Inc.
 Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Janssen Oncology, Inc. engages in the development of pharmaceutical products for the treatment of cancer. It conducts pharmaceutical product trials. The company is headquartered in Los Angeles, CA. | Chief Tech/Sci/R&D Officer | 01.09.2011 |
Cougar Biotechnology, Inc. /Old/
 Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | Chief Tech/Sci/R&D Officer | 13.07.2009 |
| SURROZEN, INC. | Director/Board Member | - |
| The University of California, San Francisco | Corporate Officer/Principal | - |
Ausbildung von Christopher Haqq
| Stanford University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| AMGEN INC. | Health Technology |
| ELICIO THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Cougar Biotechnology, Inc. /Old/
Cougar Biotechnology, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Cougar Biotechnology, Inc. is a private biotechnology company. It is engaged in the field of oncology. Cougar Biotechnology has the financial backing of a well-established venture capital group that has a long-term, successful track record in oncology drug development and biotechnology research. The company is located in Los Angeles, CA. | Health Technology |
Elicio Therapeutics, Inc. (Old)
Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA. | Health Technology |
Consonance-HFW Acquisition Corp.
 Consonance-HFW Acquisition Corp. Financial ConglomeratesFinance Consonance-HFW Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisitions, share purchase, reorganization, or similar business combination. The company was founded by Gad Soffer and Kevin Harold Livingston on August 21, 2020 and is headquartered in Princeton, NJ. | Finance |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Janssen Oncology, Inc. engages in the development of pharmaceutical products for the treatment of cancer. It conducts pharmaceutical product trials. The company is headquartered in Los Angeles, CA. | Health Technology |
